May 2024 - Page 21 of 21

ThursdayMay 02, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Announces Fast-Anneal Feature Availability in Leap(TM) Quantum Cloud Service

Fast anneal is expected to impact various quantum computing applications, from advanced scientific research in quantum simulation to AI and solving real-world problems across wide spectrum of industries It expands upon D-Wave's groundbreaking optimization achievements, utilizing the comprehensive coherent annealing quantum computing provided by D-Wave's Advantage(TM) systems and the cutting-edge Advantage2(TM) prototype The introduction of the fast-anneal feature is poised to attract both commercial and academic researchers aiming to develop top-tier applications, broaden benchmarking investigations, and correlate heightened coherence with enhanced performance D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world's first commercial…

WednesdayMay 01, 2024 3:22 pm

QualityStocksNewsBreaks – PODFEST, Cutting Edge Events Names IBN as Official Media Partner for PODFEST Asia

PODFEST and its parent company, Cutting Edge Events, have selected InvestorBrandNetwork (“IBN”), a pioneer in corporate communications and content distribution, to be the official media partner for its upcoming PODFEST Asia. The in-person podcasting conference is slated for May 8, 2024, in Manila. PODFEST Asia is designed to provide a unique opportunity for participants to engage with podcast enthusiasts, gather insights from industry experts, explore the latest trends and discover potential synergies with seasoned podcasters and newcomers alike. The one-day event represents a collaborative effort between PODFEST, Podcast Network Asia and MGS Global Group. Recognized as the longest-running annual podcasting conference…

WednesdayMay 01, 2024 2:40 pm

QualityStocksNewsBreaks – Proof of Pitch Promises to Provide Unique Transformative Platform to Showcase Web3 Innovation

Proof of Pitch represents a ground-breaking shift from traditional pitch competitions, emerging as a transformative platform that uniquely combines artificial intelligence (AI) insights with the strategic acumen of the world’s leading Web3 venture capitalists. Proof of Pitch calls upon startups at the cutting edge of Web3 innovation to dazzle the industry’s titans, venture through the vanguard of technology, and stake a claim in the digital future. It promises to provide an unmatched opportunity for innovators to present their visionary ideas, drive their startups forward, make a lasting imprint in the realm of digital innovation, and transcend traditional pitch norms. The…

WednesdayMay 01, 2024 2:31 pm

QualityStocksNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Schedules Q1 2024 Earnings Release, Conference Call

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions, today announced that it will provide a business update and release its financial results for the first quarter of 2024 following the close of the market on Monday, May 13, 2024. Cepton will hold a conference call and webcast that same day at 2:30 p.m. PT (5:30 p.m. ET). Interested parties should dial 1-877-423-9813 (toll-free) or 1-201-689-8573 (international) to join the live call and visit https://investors.cepton.com to access the webcast. A telephonic replay of the conference call will be available approximately three hours after the live…

WednesdayMay 01, 2024 2:26 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Rob Etherington, President, Director and CEO of Clene, was featured in a recent release of From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch. During the interview, Etherington discussed Clene’s work to address the critical unmet medical…

WednesdayMay 01, 2024 2:17 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share; the shares and warrants were originally issued in October 2023 and February 2024, respectively. The company noted that following this exercise, there are no remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. According…

WednesdayMay 01, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024 PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company…

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…

Site Search

Company Search

Month: May 2024